Liquidia Corp’s chief medical officer sells $50,398 in stock

In a recent transaction reported to the Securities and Exchange Commission, Dr. Rajeev Saggar, the Chief Medical (TASE:BLWV) Officer of Liquidia Corp (NASDAQ:LQDA), a $1.16 billion market cap biotech company, has sold a portion of his holdings in the company. According to InvestingPro data, the stock is currently trading near its Fair Value. On April 14, 2025, Dr. Saggar sold 3,714 shares of Liquidia Corp’s common stock at a price of $13.57 per share, amounting to a total transaction value of $50,398.

This sale was conducted under a pre-established Rule 10b5-1 trading plan that Dr. Saggar adopted on December 15, 2023. The shares sold were intended to cover tax obligations related to the vesting of restricted stock units (RSUs) that were initially granted on January 11, 2023, and vested on April 14, 2025.

Following this transaction, Dr. Saggar retains ownership of 265,602 shares, which includes a combination of unvested RSUs and shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan. With the company’s next earnings report scheduled for May 8, 2025, analysts maintain a bullish outlook, with price targets ranging from $20 to $35 per share. Discover more detailed analysis and 7 additional key insights about LQDA with an InvestingPro subscription.

In other recent news, Liquidia Corporation reported its financial results for the fourth quarter of 2024, revealing a net loss and revenue figures below analyst expectations. The company posted a Q4 2024 earnings per share (EPS) of -$0.45, missing the forecast of -$0.3821, with revenue at $2.92 million, falling short of the anticipated $4.54 million. Despite these results, Liquidia is optimistic about the upcoming launch of its product, Yutrepia, projected for May 2025. The U.S. Food and Drug Administration (FDA) has accepted Liquidia’s resubmission for Yutrepia, setting a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, for a final decision.

Analysts have responded to these developments with varying outlooks. Scotiabank (TSX:BNS) raised Liquidia’s stock target to $34, maintaining a Sector Outperform rating, citing the company’s preparedness for Yutrepia’s commercial launch. H.C. Wainwright reiterated a Buy rating with a $29 target, expressing confidence in Liquidia’s legal position and market opportunity. Raymond (NSE:RYMD) James affirmed a Strong Buy rating, with a $27 target, based on optimistic expectations for Yutrepia’s launch.

Liquidia has also secured a $100 million financing agreement with HealthCare Royalty to support the development and commercialization of Yutrepia and another product, L606. This financing will be distributed in three portions, contingent on commercial milestones. The company is actively preparing for Yutrepia’s market entry, with a sales team ready to commence activities upon potential approval.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.